FOI_7068

Internal Reference Number: FOI_7068

Date Request Received: 13/03/2023 00:00:00

Date Request Replied To: 03/04/2023 00:00:00

This response was sent via: By Email

Request Summary: Oesophageal and Gastric cancer

Request Category: Companies


Question Number 1: How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with: • CAPOX (Capecitabine with Oxaliplatin) • FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) • Lonsurf (Trifluridine - tipiracil) • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only

Answer To Question 1: <5 patients treated with FOLFOX <5 patients treated with other systemic anticancer therapy <5 patients treated with palliative care only 0 patients for the rest of the treatment options

Question Number 2: How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with: • Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) • Nivolumab monotherapy • Nivolumab and Ipilimumab • Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) • Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidene (5-Fluorouracil or Capecitabine) • Any other systemic anti-cancer therapy • Palliative care only

Answer To Question 2: <5 patients treated with Platinum and Fluoropyrimidene based combination treatments <5 patients treated with Pembrolizumab in combination with Platinum <5 patients treated with other systemic anticancer therapy <5 patients treated with palliative care only 0 patients for the rest of the treatment options

Question Number 3: Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.

Answer To Question 3: Add- Aspirin 77 participants

Question Number 4: Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.

Answer To Question 4: No trials in this area

To return to the list of all the FOI requests please click here

Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.